ARCH Venture Partners
ARCH Venture Partners is a venture capital firm that has been backing disruptive science companies for over 30 years. They are known for their contrarian, bold, and imaginative approach to investing, focusing on revolutionary technologies that can significantly impact people's lives. ARCH takes a long-term view in building companies, offering flexible investment sizes and leveraging an extensive network of partners to help companies grow from formation to full potential. Their mission is to catalyze discoveries that prevent, detect, and cure diseases, partnering with great science and amazing people to build disruptive companies globally.
Portfolio
Illumina is a leading company in the field of genomics, providing sequencing and array-based solutions for genetic analysis.
#Biotechnology
Alnylam Pharmaceuticals is known for its work in RNA interference therapeutics.
#Biotechnology
Juno Therapeutics focuses on developing innovative cellular immunotherapies for the treatment of cancer.
#Biotechnology
Receptos is involved in the development of therapeutic candidates for immune disorders.
#Biotechnology
Agios Pharmaceuticals is focused on developing treatments for cancer and rare genetic diseases.
#Biotechnology
Sage Therapeutics is dedicated to developing novel therapies for central nervous system disorders.
#Biotechnology